OBI Pharma (Taiwan) Performance
| 4174 Stock | TWD 60.30 0.50 0.82% |
The firm holds a Beta of -0.63, which implies possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning OBI Pharma are expected to decrease at a much lower rate. During the bear market, OBI Pharma is likely to outperform the market. At this point, OBI Pharma has a negative expected return of -0.32%. Please make sure to check OBI Pharma's mean deviation, standard deviation, total risk alpha, as well as the relationship between the coefficient of variation and jensen alpha , to decide if OBI Pharma performance from the past will be repeated in the future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days OBI Pharma has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of abnormal performance in the last few months, the Stock's basic indicators remain fairly stable which may send shares a bit higher in January 2025. The latest fuss may also be a sign of long-term up-swing for the venture sophisticated investors. ...more
| Begin Period Cash Flow | 3.3 B | |
| Total Cashflows From Investing Activities | 82.7 M |
OBI |
OBI Pharma Relative Risk vs. Return Landscape
If you would invest 7,530 in OBI Pharma on September 12, 2024 and sell it today you would lose (1,450) from holding OBI Pharma or give up 19.26% of portfolio value over 90 days. OBI Pharma is generating negative expected returns and assumes 2.0346% volatility on return distribution over the 90 days horizon. Simply put, 18% of stocks are less volatile than OBI, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
OBI Pharma Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for OBI Pharma's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as OBI Pharma, and traders can use it to determine the average amount a OBI Pharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1592
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | 4174 |
Estimated Market Risk
| 2.03 actual daily | 18 82% of assets are more volatile |
Expected Return
| -0.32 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.16 actual daily | 0 Most of other assets perform better |
Based on monthly moving average OBI Pharma is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of OBI Pharma by adding OBI Pharma to a well-diversified portfolio.
OBI Pharma Fundamentals Growth
OBI Stock prices reflect investors' perceptions of the future prospects and financial health of OBI Pharma, and OBI Pharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on OBI Stock performance.
| Return On Equity | -0.34 | |||
| Return On Asset | -0.22 | |||
| Operating Margin | (311.15) % | |||
| Current Valuation | 12.29 B | |||
| Shares Outstanding | 228.95 M | |||
| Price To Book | 3.33 X | |||
| Price To Sales | 2,517 X | |||
| Revenue | 18.77 M | |||
| EBITDA | (1.52 B) | |||
| Cash And Equivalents | 3.57 B | |||
| Cash Per Share | 17.92 X | |||
| Total Debt | 28 M | |||
| Debt To Equity | 0.06 % | |||
| Book Value Per Share | 22.55 X | |||
| Cash Flow From Operations | (1.06 B) | |||
| Earnings Per Share | (8.05) X | |||
| Total Asset | 4.49 B | |||
About OBI Pharma Performance
Evaluating OBI Pharma's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if OBI Pharma has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if OBI Pharma has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
OBI Pharma, Inc., a bio-pharma company, develops and licenses novel therapeutic agents for unmet medical needs against cancer in Taiwan and internationally. The company was founded in 2002 and is based in Taipei, Taiwan. OBI PHARMA operates under Biotechnology classification in Taiwan and is traded on Taiwan OTC Exchange.Things to note about OBI Pharma performance evaluation
Checking the ongoing alerts about OBI Pharma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for OBI Pharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| OBI Pharma generated a negative expected return over the last 90 days | |
| The company reported the revenue of 18.77 M. Net Loss for the year was (1.53 B) with loss before overhead, payroll, taxes, and interest of (25.59 M). | |
| OBI Pharma has accumulated about 3.57 B in cash with (1.06 B) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 17.92. | |
| Roughly 37.0% of the company shares are owned by insiders or employees |
- Analyzing OBI Pharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether OBI Pharma's stock is overvalued or undervalued compared to its peers.
- Examining OBI Pharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating OBI Pharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of OBI Pharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of OBI Pharma's stock. These opinions can provide insight into OBI Pharma's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for OBI Stock Analysis
When running OBI Pharma's price analysis, check to measure OBI Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy OBI Pharma is operating at the current time. Most of OBI Pharma's value examination focuses on studying past and present price action to predict the probability of OBI Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move OBI Pharma's price. Additionally, you may evaluate how the addition of OBI Pharma to your portfolios can decrease your overall portfolio volatility.